Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Clinton M Hasenour"'
Autor:
Clinton M Hasenour, Martha L Wall, D Emerson Ridley, Freyja D James, Curtis C Hughey, E Patrick Donahue, Benoit Viollet, Marc Foretz, Jamey D Young, David H Wasserman
Publikováno v:
PLoS ONE, Vol 12, Iss 8, p e0183601 (2017)
[This corrects the article DOI: 10.1371/journal.pone.0170382.].
Externí odkaz:
https://doaj.org/article/d354663b96f6454c8c652e11dd6eaeac
Autor:
Clinton M Hasenour, D Emerson Ridley, Freyja D James, Curtis C Hughey, E Patrick Donahue, Benoit Viollet, Marc Foretz, Jamey D Young, David H Wasserman
Publikováno v:
PLoS ONE, Vol 12, Iss 1, p e0170382 (2017)
AMPK is an energy sensor that protects cellular energy state by attenuating anabolic and promoting catabolic processes. AMPK signaling is purported to regulate hepatic gluconeogenesis and substrate oxidation; coordination of these processes is vital
Externí odkaz:
https://doaj.org/article/80c12fbc0933474e984e7517decadd1a
Autor:
Tomasz K. Bednarski, Mohsin Rahim, Clinton M. Hasenour, Deveena R. Banerjee, Irina A. Trenary, David H. Wasserman, Jamey D. Young
Publikováno v:
Journal of Lipid Research, Vol 65, Iss 6, Pp 100558- (2024)
Metabolic dysfunction-associated steatotic liver disease is the most common form of liver disease and poses significant health risks to patients who progress to metabolic dysfunction-associated steatohepatitis. Fatty acid overload alters endoplasmic
Externí odkaz:
https://doaj.org/article/c47f295c40d14743bbad10fcd129e345
Publikováno v:
Diabetes. 71
The metabolic complications of obesity are distributed throughout the body, yet studies assessing its impact on metabolic fluxes have primarily focused on single tissues. Here we use a 13C tracer approach to simultaneously quantify metabolic flux dys
Autor:
Kevin M. Pantalone, Juan M. Maldonado, Oralee J. Varnado, Clinton M. Hasenour, Kashif M. Munir, Charles Atisso, Manige Konig
Publikováno v:
Diabetes, Obesity & Metabolism
Despite treatment advances leading to improved outcomes over the past 2 decades, cardiovascular (CV) disease (CVD) remains the leading cause of morbidity and mortality in people with diabetes. People with type 2 diabetes (T2D) have a 2‐ to 4‐fold
Autor:
Jamey D. Young, Kelli L. Boyd, Brandon J. Eudy, Arion Kennedy, Irina Trenary, Robin P. da Silva, Clinton M. Hasenour, Tomasz Bednarski
Publikováno v:
Journal of Lipid Research, Vol 61, Iss 5, Pp 707-721 (2020)
J Lipid Res
J Lipid Res
Fatty liver involves ectopic lipid accumulation and dysregulated hepatic oxidative metabolism, which can progress to a state of elevated inflammation and fibrosis referred to as nonalcoholic steatohepatitis (NASH). The factors that control progressio
Autor:
Clinton M. Hasenour, Tomasz Bednarski, Mohsin Rahim, Jamey D. Young, Curtis C. Hughey, David H. Wasserman
Publikováno v:
JCI Insight
The liver is the major source of glucose production during fasting under normal physiological conditions. However, the kidney may also contribute to maintaining glucose homeostasis in certain circumstances. To test the ability of the kidney to compen
Autor:
Jamey D. Young, Tomasz Bednarski, Curtis C. Hughey, David H. Wasserman, Clinton M. Hasenour, Mohsin Rahim
Publikováno v:
Diabetes. 70
The liver is the major source of glucose production during fasting under normal physiological conditions. However, the kidney may also contribute to maintaining glucose homeostasis in certain circumstances. To test the ability of the kidney to compen
Autor:
null Kevin M. Pantalone, null Kashif Munir, null Clinton M. Hasenour, null Charles M. Atisso, null Oralee J. Varnado, null Juan M. Maldonado, null Manige Konig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3be05ffb128a5b24838fcf353eecd8b4
https://doi.org/10.1111/dom.14165/v3/response1
https://doi.org/10.1111/dom.14165/v3/response1
Autor:
Manige Konig, Hertzel C. Gerstein, Clinton M. Hasenour, Helen M. Colhoun, Reema Mody, Kelley R. Branch, Charles Atisso, Mark Lakshmanan, Matthew C. Riddle
Publikováno v:
Diabetes. 69
The REWIND trial showed that relative to placebo (PL), once weekly dulaglutide (DU) 1.5 mg reduced the incidence of a major adverse cardiovascular (CV) event (MACE; nonfatal myocardial infarction, nonfatal stroke, or CV death) in patients with T2D wi